Behice ALMIŞ HAN, Habip ALMİŞ, Mustafa ÇELİK, Funda GÜMÜŞTAŞ, MEHMET TURGUT

Dikkat eksikliği hiperaktivite bozukluğu olan prepubertal bir erkek çocukta metilfenidatın indüklediği jinekomasti: Bir olgu sunumu

Metilfenidat, dikkat eksikliği hiperaktivite bozukluğunda sıklıkla kullanılan bir tedavi seçeneğidir. Bu yazıda prepubertal bir erkek çocukta uzun salınımlı metilfenidat tedavisinden sonra aniden gelişen bilateral jinekomastiyi sunacağız ve bu konuda literatürü tartışacağız. Düzeneği bilinmemesine rağmen metilfenidat kullanan olgularda jinekomastinin nadir de olsa gelişebileceği akılda tutulmalıdır. (Anadolu Psikiyatri Derg 2016; 17(Ek.3):74-76).

Methylphenidate induced gynecomastia in a prepubertal boy: a case report

Methylphenidate is a frequently used treatment choice in attention deficit hyperactivity disorder. In this paper, we will present a prepubertal boy who suddenly developed bilateral gynecomastia after sustained release methylphenidate (OROS MPH) treatment and we will discuss literature on this topic. Although the mechanism is not known, rare development of gynecomastia should be kept in mind in cases using methylphenidate. (Anatolian Journal of Psychiatry 2016; 17(Suppl.3):74-76).

___

1. Abacı A, Büyükgebiz B. Adolesan jinekomasti. Turkiye Klinikleri J Pediatr Sci 2006; 2(10):296- 308.

2. Braunstein GD. Gynecomastia. N Engl J Med 1993; 328(7):490-495.

3. Einav-Bachar R, Phillip M, Aurbach-Klipper Y, Lazar L. Prepubertal gynaecomastia: aetiology, course and outcome. Clin Endocrinol (Oxf.) 2004; 61(1):55-60.

4. American Psychiatric Association Diagnostic and Statistical Manual of Mental Disorders. Fifth Edition. Washington, DC: American Psychiatric Association, 2013.

5. Weiss G. Attention deficit hyperactivity disorder. M Lewis (Ed.), Comprehensive Textbook of Child and Adolescent Psychiatry, second ed., Baltimore: Williams & Wilkins, 1996, p.544-563.

6. Hoevenaren IA, Schott DA, Otten BJ, KroeseDeutman HC. Prepubertal unilateral gynecomastia: a report of two cases. Eur J Plast Surg 2011; 34(5):395-398.

7. Li RZ, Xia Z, Lin HH, Wen Y, Wu J, Wang HW. Childhood gynecomastia: a clinical analysis of 240 cases. Zhongguo Dang Dai Er Ke Za Zhi 2007; 9(5):404-406.

8. Bowman JD, Hyunah Kim H, Bustamante JJ. Drug-induced gynecomastia. Pharmacotherapy 2012; 32(12):1123-1140.

9. Swanson J, Gupta S, Lam A, Shoulson I, Lerner M, Modi N, et al. Development of a new once-aday formulation of methylphenidate for the treatment of attention-deficit/hyperactivity disorder: proof-of-concept and proof-of-product studies. Arch Gen Psychiatry 2003; 60(2):204-211.

10. King S, Griffin S, Hodges Z, Weatherly H, Asseburg C, Richardson G, et al. A systematic review and economic model of the effectiveness and cost-effectiveness of methylphenidate, dexamfetamine and atomoxetine for the treatment of attention deficit hyperactivity disorder in children and adolescents. Health Technol Assess 2006; 10(23):iii-iv,xiii-146.

11. Ensat F, Edelbauer M, Wechselberger G. Unilateral gynecomastia in a prepubertal boy. Eur J Pediatr 2012; 171(1):197.

12. Coşkun M, Adak I, Akaltun I. Bilateral gynecomastia in a preadolescent boy while under treatment with methylphenidate and paroxetine. J Clin Psychopharmacol 2014; 34(4):537-538.

13. Bembo SA, Carlson HE. Gynecomastia: Its features, and when and how to treat it. Cleve Clin J Med 2004; 71(6):511-517.